Oncolytics Biotech (ONCY)
is focused on the development of oncolytic viruses for use as cancer
therapeutics. The Company’s lead product, REOLYSIN, a proprietary
formulation of the human reovirus, is currently in late stage (Phase III)
clinical testing in head and neck cancers. REOLYSIN has been utilized in
nearly thirty clinical trials including translational, Phase I, Phase II
(single arm and randomized), and Phase III studies in a broad range of
initial positive top line data from the first endpoint in its
double-blinded randomized Phase III clinical study examining REOLYSIN in
combination with carboplatin and paclitaxel in second-line patients with
platinum-refractory, taxane-naïve head and neck cancers
Announced three poster
presentations covering expanded results from: a Phase II clinical trial
using intravenous administration of REOLYSIN in combination with
paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC)
with Kras or EGFR-activated tumours (REO 016).
Expanded enrollment in the
first stage of our Phase III head and neck cancer clinical trial (REO
18) to include 167 patients, all of whom have now been enrolled, and
introduced an additional patient segregation to differentiate between
patients with local recurrent disease, with or without metastases, and
patients with distal metastases while maintaining the blind.
Completed enrollment in a
U.K. Phase I clinical trial using intravenously-administered REOLYSIN in
combination with cyclophosphamide in patients with advanced malignancies.
News and Press Releases
Biotech Inc. Announces Positive Top Line REOLYSIN® Data for First Endpoint
in Randomized Phase III Study in Head and Neck Cancers
Biotech Inc. Announces Addition to Senior Management Team
Biotech® Inc. Collaborators Present Positive REOLYSIN® Trial Results and
Research at EORTC-NCI-AACR Symposium
Biotech® Inc. Announces Third Quarter 2012 Results
For the latest Quote
and News on ONCY Click
Thompson PhD - President and Chief Executive Officer
Dr. Thompson has held the
positions of Chairman of the Board, President and Chief Executive Officer of
Oncolytics Biotech Inc. since April 1999. He has provided leadership to
various organizations within the biotechnology sector for more than twenty
years. Prior to his role with Oncolytics, Dr. Thompson was the Chief
Executive Officer of SYNSORB Biotech from 1994 to 1999. From 1983 to 1994,
Dr. Thompson worked in a senior role at the Alberta Research Council. He is
the current Chairman of BIOTECanada. He received his PhD from the University
of Western Ontario in the Department of Microbiology and Immunology.
Coffey PhD - Chief Operating Officer
A co-founder of Oncolytics Biotech Inc., Dr.
Coffey’s current responsibilities include directing the Company's research
and development efforts, and integrating these efforts into an effective
clinical trial program and intellectual property position for the Company.
Dr. Coffey completed his doctorate degree in oncology at the University of
Calgary with a focus on the oncolytic capabilities of the reovirus. The
results of his research have been published in various respected scientific
journals, including Science, Human Gene Therapy, and The EMBO Journal. Dr.
Coffey has held the position of Chief Operations Officer of the Corporation
since December 2008, Chief Operating Officer from December 2004 to December
2008, Vice-President of Product Development from July 1999 to December 2004
and Chief Financial Officer from September 1999 to May 2000.
Look CA - Chief Financial Officer
Mr. Look is a Chartered Accountant with more
than fifteen years of experience in accounting, finance, tax and treasury.
He is responsible for the financial reporting and related regulatory
filings, budget and treasury functions, and tax compliance of Oncolytics.
Mr. Look joined Oncolytics in as the Company’s Controller in April 2003,
and assumed the role of Chief Financial Officer in November 2012.
Prior to joining Oncolytics, from 2000 to April 2003, Mr. Look was Manager
of Audit and Assurance Services with Ernst & Young LLP in Canada.
From 1998 to the end of 1999, Mr. Look held the positions of Audit Manager
and Senior Accountant at Ernst & Young LLP in Chile.
ONCY filings with the SEC can be
1167 Kensington Crescent NW
Calgary, AB T2N 1X7
feature stock reports are intended to be stock ideas, not recommendations.
Please do your own research before investing. It is crucial that you at
least look at current SEC filings and read the latest press releases. Information contained in this report was extracted from current documents
filed with the SEC, the company website and other publicly available
sources deemed reliable. For more information see our disclaimer section, a
link of which can be found on our website. This document contains
forward-looking statements, particularly as related to the business plans of
the Company, within the meaning of Section 27A of the Securities Act of 1933
and Sections 21E of the Securities Exchange Act of 1934, and is subject to
the safe harbor created by these sections. Actual results may differ
materially from the Company's expectations and estimates. The information
provided in this report is not intended for distribution to, or use by, any
person or entity in any jurisdiction or country where such distribution or
use would be contrary to law or regulation or which would subject us to any
registration requirement within such jurisdiction or country.
SmallCapReview. All rights reserved. SCR is not a
Registered Broker/Dealer or Financial Advisor. All materials presented on our website and individual reports
released to the public through this website, e-mail or any other means of
transmission are not to be regarded as investment advice and are only
for informative purposes. Before making a purchase or sale of any securities featured
on our web site or mentioned in our reports, we strongly encourage and
recommend consultation with a registered securities representative. This
is not to be construed as a solicitation or recommendation to buy or sell
with any stock, companies we select to profile involve a
degree of investment risk and volatility, particularly small-caps. All investors are cautioned that they may lose all or a portion of
their investment if they decide to make a purchase in any of our profiled
companies. Past performance of our profiled stocks is not indicative of
future results. The profile and opinions expressed herein are expressed
as of the date the profile is posted on site and are subject to change
without notice. No investor should assume that reliance on the views,
opinions or recommendations contained herein will produce profitable results.
SmallCapReview may hold positions in securities mentioned herein, and may
make purchases or sales in such securities featured on our website or within
In order to
be in full compliance with the Securities Act of 1933, Section 17(b), SCR will disclose in it's disclaimer, what, if any
compensation was received for our efforts in researching, presenting
and disseminating this information to our subscriber database and featuring
the report on the SmallCapReview website. SmallCapReview has
not been compensated for its efforts with regards to Oncolytics
encourage our readers to invest carefully and read the investor information
available at the web sites of the Securities and Exchange Commission (SEC)
and/or the National Association of Securities Dealers (NASD) at: http://www.nasd.com
. Readers can review all public filings by companies at the SEC's EDGAR
page. The NASD has published information on how to invest carefully at its